Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1986;74:367-373

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gage, J.
Right arrow Articles by LeJemtel, T. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gage, J.
Right arrow Articles by LeJemtel, T. H.

Circulation, Vol 74, 367-373, Copyright © 1986 by American Heart Association


ARTICLES

Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure

J Gage, H Rutman, D Lucido and TH LeJemtel

The effects of amrinone, dobutamine, and a combination of the two drugs on peak positive left ventricular dP/dt and left ventricular performance were evaluated in 11 patients with chronic congestive heart failure. When administered alone, both dobutamine (10.9 micrograms/kg/min) and intravenous amrinone (1.9 mg/kg/min) significantly increased left ventricular dP/dt and performance. When compared with dobutamine alone, the addition of amrinone resulted in further increases in left ventricular dP/dt and cardiac index (to 1319 +/- 419 from 1202 +/- 376 mm Hg/sec, p less than .002, and to 3.56 +/- 0.78 from 3.04 +/- 0.67 liters/min/m2, p less than .01, respectively). The combination also induced a further reduction in left ventricular end-diastolic pressure (to 15.3 +/- 11.3 from 18.2 +/- 10.3 mm Hg, p less than .05) when compared with amrinone alone. The combination of dobutamine and amrinone increased heart rate slightly when compared with either drug alone, but did not further reduce systemic arterial pressure when compared with amrinone alone. The dose-response curve of left ventricular dP/dt and performance during titration of dobutamine with and without the addition of intravenous amrinone was evaluated in seven patients. The addition of amrinone to any dose of dobutamine produced higher cardiac index and lower systemic vascular resistance than dobutamine or amrinone alone. Thus, when compared with dobutamine alone in patients with chronic congestive heart failure, the addition of intravenous amrinone to dobutamine results in an additive improvement in left ventricular performance throughout the dose range.


This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
L.-G. Dahlin and B. Peterzen
Impella Used for Hemostasis by Left Ventricular Unloading, in a Case With Left Ventricular Posterior Wall Rupture
Ann. Thorac. Surg., April 1, 2008; 85(4): 1445 - 1447.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
A. Y. Denault, Y. Lamarche, P. Couture, F. Haddad, J. Lambert, J.-C. Tardif, and L. P. Perrault
Inhaled milrinone: a new alternative in cardiac surgery?
Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2006; 10(4): 346 - 360.
[Abstract] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
M. B. Vroom
An overview of inotropic agents.
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2006; 10(3): 246 - 252.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
Y. Shi, A. Y. Denault, P. Couture, A. Butnaru, M. Carrier, and J.-C. Tardif
Biventricular diastolic filling patterns after coronary artery bypass graft surgery
J. Thorac. Cardiovasc. Surg., May 1, 2006; 131(5): 1080 - 1086.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
K. P. Bouki, G. Pavlakis, and E. Papasteriadis
Management of Cardiogenic Shock Due to Acute Coronary Syndromes
Angiology, March 1, 2005; 56(2): 123 - 130.
[Abstract] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
M. B. Vroom
Epidemiology and Pharmacotherapy of Acute Heart Failure
Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 3 - 12.
[PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
M. Bristow
{beta}-Adrenergic Receptors and Phosphodiesterase: Present and Future Perspectives
Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 19 - 21.
[PDF]


Home page
QJMHome page
C.H. Davies
Revascularization for cardiogenic shock
QJM, February 1, 2001; 94(2): 57 - 67.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
S. M. Hollenberg, C. J. Kavinsky, and J. E. Parrillo
Cardiogenic Shock
Ann Intern Med, July 6, 1999; 131(1): 47 - 59.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
M. B. Vroom
Pharmacologic Management of Acute Heart Failure: A Review
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 191 - 203.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
A. K. Pridjian, E. D. Frohlich, C. H. VanMeter, P. M. McFadden, and J. L. Ochsner
Pharmacologic Support With High-Energy Phosphate Preservation in the Postischemic Neonatal Heart
Ann. Thorac. Surg., June 1, 1995; 59(6): 1435 - 1440.
[Abstract] [Full Text]


Home page
J Intensive Care MedHome page
G. S. Francis and S. L. Archer
Diagnosis and Management of Acute Congestive Heart Failure in the Intensive Care Unit
J Intensive Care Med, March 1, 1989; 4(2): 84 - 92.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
A. S. Maisel, C. M. Wright, S. M. Carter, M. Ziegler, and H. J. Motulsky
Tachyphylaxis with Amrinone Therapy: Association with Sequestration and Down-Regulation of Lymphocyte Beta-Adrenergic Receptors
Ann Intern Med, February 1, 1989; 110(3): 195 - 201.
[Abstract] [PDF]